Showing 41-50 of 842 results for "".
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- Bonti Takes Aim at Scar Reduction with Shine Clinical Programhttps://practicaldermatology.com/news/bonti-takes-aim-at-scar-reduction-with-shine-clinical-program/2457897/Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized
- Cutera Unveils Free Digital Resources to Help Practices Thrive Through COVID-19 and Beyondhttps://practicaldermatology.com/news/cutera-unveils-new-free-digital-resources-to-help-practices-thrive-through-covid-19-and-beyond/2460366/CUTERA, INC. is launching the Cutera University e-learning series to support medical professionals through the COVID-19 crisis and beyond. The Cutera University e-learning series offers compli
- Bonti's Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgeryhttps://practicaldermatology.com/news/bontis-novel-neurotoxin-shines-in-early-study-of-scar-reduction-after-mohs-surgery/2457662/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
OTC Skincare Today
https://practicaldermatology.com/issues/supplements/otc-skincare-today/23247/Can dermatologists afford to ignore patients’ growing use of OTC products?- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://practicaldermatology.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.